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OBJECTIVE: The aim of this study was to determine the
performance characteristics of the14C-urea breath test
(UBT) performed 2 wk after the completion of therapy for
Helicobacter pyloriusing a 4 to 6 wkstudy as the gold
standard.
METHODS: Patients with activeHelicobacter pylori infec-
tion at four medical centers received proton pump inhibitor-
based triple or quadruple therapy for 10–14 days. Patients
underwent the14C-UBT 2 and 4–6 wk after the completion
of therapy. A positive test was defined as14CO2 excretion of
.200 dpm, a negative test as,50 dpm, and an equivocal
test as.50 but,200 dpm. Performance characteristics of
the 2-wk UBT were calculated using the 4 to 6-wk result as
a gold standard.
RESULTS: Eighty-five patients were enrolled and 82 patients
(mean6 SD age, 626 15 yr; 15 women) completed the
protocol. Four patients had equivocal UBT results and were
excluded from the analysis. Of the 78 patients, 68 (87%) had
a negative 4 to 6-wk UBT. The 2-week UBT yielded a
sensitivity of 90% (95% confidence interval 72–100%),
specificity of 99% (97–100%), and accuracy of 97% (93–
100%). In patients with a persistently positive UBT,14CO2
excretion at 2 wk was significantly lower than at 4–6 wk
after therapy (p 5 0.03).
CONCLUSIONS: A UBT performed 2 wk after therapy
yielded results comparable to 4 to 6 wk testing. Further
studies to evaluate the optimal time of confirmatory testing
in the age of more effective proton pump inhibitor-based
triple therapies are warranted. (Am J Gastroenterol 2000;95:
1171–1174. © 2000 by Am. Coll. of Gastroenterology)
INTRODUCTION
Helicobacter pylori(H. pylori) infection has been linked to
the pathogenesis of peptic ulcer disease (PUD) (1) and
gastric malignancy (2). The eradication ofH. pylori in
patients with PUD significantly reduces the likelihood of
ulcer recurrence (1). More recently a number of medical
organizations have advocated the eradication ofH. pylori in
young patients with uncomplicated dyspeptic symptoms (3).
H. pylori is usually treated with an acid suppressive medi-
cation in combination with antimicrobials. Eradication rates
with the currently available therapeutic regimens vary con-
siderably, ranging from 50 to 95% (4).
Currently, testing to proveH. pylori eradication is only
recommended in patients with a complicated gastric or
duodenal ulcer, mucosa-associated lymphoid tissue lym-
phoma, after resection of an early gastric cancer, and in
patients with persistent dyspeptic symptoms despite appro-
priate therapy (5).H. pylori eradication can be established
reliably by histology, rapid urease testing, and the urea
breath test (UBT) (5). Preliminary studies suggest that the
stool antigen test may also be useful as a means of testing
for eradication, although this requires confirmation in the
United States (6).
The UBT uses labeled urea (13C or 14C) that, in the
presence ofH. pylori, is metabolized by urease to yield CO2.
The labeled gas is absorbed across the gastric mucosa and
subsequently measured in the patient’s expired breath. Both
the 13C- and14C-UBT have been approved for commercial
use by the Food and Drug Administration. Because of fa-
vorable cost, accuracy, convenience, and safety, the UBT
has become the standard means of determiningH. pylori
eradication (7, 8). Largely related to the fear of false-
negative test results, it is currently recommended that erad-
ication testing be performed no less than 4 wk after the
completion of antimicrobial therapy (9). Although this rec-
ommendation has been accepted by clinicians and clinical
investigators, few studies have attempted to determine the
optimal timing of eradication testing.
We attempted to determine the performance characteris-
tics of the14C-UBT performed 2 wk after the completion of
therapy using the standard 4- to 6-wk assessment forH.
pylori eradication as gold standard.
Part of this work was presented at Digestive Diseases Week, Orlando, Florida,
May 1999.
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PATIENTS AND METHODS
Patient Population
Patients with activeH. pylori infection documented by
histology (at least one biopsy each from the body and
antrum evaluated by an experienced gastrointestinal pathol-
ogist after hematoxylin and eosin staining), rapid urease
testing (Pyloritek, Serim Research, Elkhart, IN; CLOtest,
Ballard Medical Products, Draper, UT) or urea breath test-
ing (Pytest, Ballard Medical Products, Draper, UT) within
30 days of recruitment were asked to participate in this study
at four geographically diverse medical centers within the
United States. The choice of therapy forH. pylori was left
to the discretion of the physician who identified the presence
of the infection. Children under the age of 18 yr, pregnant
women, and those unable to understand or provide written
informed consent were not eligible. This protocol was ap-
proved by the Institutional Review Board at each of the
participating study sites.
Experimental Protocol
After providing written informed consent, eligible patients
were asked to undergo the14C-urea breath test 2 wk and
4–6 wk after the completion of therapy forH. pylori.
Patients were instructed not to take antibiotics, bismuth-
containing compounds, or proton pump inhibitors (PPI)
between the completion of therapy forH. pylori and their
return for breath testing. The UBT was performed according
to the manufacturer’s instructions. A single 10-min breath
sample was collected and analyzed using a calibrated scin-
tillation counter at each of the participating study sites.
Appropriate quality control measures were carried out to
assure the accuracy of the scintillation counter at each study
site. A positive test was defined as14CO2 excretion of.200
disintegrations per minute (dpm); a negative test was de-
fined as,50 dpm; and an equivocal test was defined as.50
but ,200 dpm.
Statistical Analysis
The sensitivity, specificity, positive predictive value, nega-
tive predictive value (NPV), accuracy, and associated 95%
confidence intervals (CI) for the 2-wk UBT were deter-
mined using the 4 to 6-wk UBT as a gold standard. Patients
with equivocal UBT results were not included in the deter-
mination of performance characteristics of the 2-wk UBT.
The mean (6SD) dpms for positive and negative studies
at 2 wk and 4–6 wk were determined. Results were com-
pared for statistically significant differences using a paired
Student’st test. A p value of,0.05 defined a statistically
significant difference between values.
RESULTS
Between 11/98 and 10/99, 85 patients with activeH. pylori
infection were enrolled in this protocol. Three patients did
not comply with the instructions provided at the start of the
protocol (1) or did not attend one of the two UBT appoint-
ments (2). Eighty-two patients (mean age6 SD of 626 15
yr), 15 women and 67 men) completed the protocol. All
patients were treated with PPI-based triple or quadruple
therapy for 10–14 days. Four patients had equivocal 2-wk
(2) or 4- to 6-wk (2) UBT results and were excluded from
further analysis (Table 1). One patient with an equivocal
2-wk UBT result and a negative 4- to 6-wk test result was
found to have a negative UBT 12 wk after therapy. The
other three patients with equivocal UBT results have not
undergone a third UBT. Sixty-eight of 78 evaluable patients
had no evidence ofH. pylori infection on the basis of the 4
to 6-wk UBT, yielding a cure rate for all therapies of 87%.
Of 10 patients with a positive UBT result at 4–6 wk, nine
had a positive test 2 wk after the completion of therapy,
yielding a sensitivity of 90% (95% CI 72–100%). Sixty-
seven of 68 patients with a negative 4- to 6-wk UBT had a
negative 2-wk test result, yielding a specificity of 99% (95%
CI 97–100%). The patient with a false-positive 2-wk UBT
result underwent a third UBT 12 wk after the completion of
therapy, which yielded a negative result. The 2-wk UBT test
result was consistent with the 4- to 6-wk test result in 76 of
78 patients (97%; 95% CI 93–100%). Performance charac-
teristics of the 2-wk UBT using the 4- to 6-wk UBT as a
gold standard are provided in Table 2.
When the excretion of14CO2 (absolute dpm values6SD)
for the 10 patients with a positive 4-wk UBT result were
evaluated, we found that14CO2 excretion at 2 wk (10076
612 dpm) was significantly lower than14CO2 excretion at
4–6 weeks (14556 590 dpm,p 5 0.03). There was no
significant difference in14CO2 excretion at 2 wk (106 25
dpm) versus4–6 wk (86 7 dpm;p 5 not significant) for
the 68 patients with negative results.
Table 1. Individuals With Equivocal UBT Results (dpm)
Therapy
UBT Results (dpm)
2 wk 4 wk
Quadruple therapy 149 0
Quadruple therapy 38 73
Quadruple therapy 7 63
Quadruple therapy 144 0
Equivocal results.50 dpm and,200 dpm.
Table 2. Performance Characteristics (%) for the 2-wk UBT Using the 4- to 6-wk UBT as a Gold Standard
Sensitivity Specificity PPV NPV Accuracy
9/10 (90%) 67/68 (99%) 9/10 (90%) 67/68 (99%) 76/78 (97%)
95% CI 72–100 97–100 72–100 97–100 93–100
PPV 5 positive predictive value; NPV5 negative predictive value; CI5 confidence interval.
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DISCUSSION
The UBT has proven a reliable means of establishing the
presence ofH. pylori infection before or after a course of
antimicrobial therapy (7, 8). Several factors including the
recent use of antibiotics, bismuth-containing compounds,
and PPIs can affect the accuracy of the UBT (10–12). A
number of reports have suggested that the accuracy of all
tests that identify activeH. pylori infection is decreased for
an unclear period after the completion of therapy (13, 14).
For this reason, it is currently recommended that testing to
establishH. pylori eradication be performed no less than 4
wk after the completion of therapy (9). Despite the wide-
spread acceptance of this recommendation, few studies have
carefully evaluated the most appropriate time to document
cure ofH. pylori infection. Neil and colleagues (9) reported
agreement between endoscopic tests (histology and in some
cases rapid urease testing or culture) forH. pylori performed
1 and 6 months after treatment in 359 of 384 patients (94%).
From this data, they concluded that confirmatory testing
should be performed 1 month after therapy. It is clear that
testing immediately after the completion of therapy can lead
to false-negative results. However, it remains unclear
whether it is necessary to delay confirmatory testing for a
full month after the completion of therapy.
In this study, we found that UBT results obtained 2 wk
after therapy agreed with those obtained 4–6 wk after
therapy in 76 of 78 patients (97%; 95% CI 93–100%). For
those with persistent infection on the basis of the 4- to 6-wk
UBT, 9 of 10 (90%) had a positive test result 2 wk after
therapy. The specificity (99%; 95% CI 97–100%) and neg-
ative predictive value (99%; 95% CI 97–100%) of the 2-wk
UBT were excellent. Breath14CO2 excretion was signifi-
cantly lower at 2 wk than at 4–6 wk in patients with
persistent infection. This finding could be the consequence
of the prolonged effects of therapy onH. pylori growth or
urease activity. A recent study found that UBT results can
remain falsely negative for up to 2 wk after the cessation of
a PPI (11). In the current study, we observed a false-
negative rate of 10% at 2 wk. Similar studies evaluating the
effects of antibiotics, either individually or in combination,
on the UBT have not been performed. Although we were not
surprised to see a false-negative 2-wk UBT result, we were
surprised to find a false-positive 2-wk UBT result. We
confirmed the 2-wk test to be truly falsely positive by
obtaining an additional UBT 12 wk after therapy, which,
like the 4- to 6-wk study, was negative. Although false-
positive UBT results after therapy have been reported by
other investigators (15), the explanation for their occurrence
remains elusive.
We acknowledge several issues that should be considered
when interpreting our results. First, it could be argued that
clinicians are using many different regimens to treatH.
pylori infection and that these different antibiotic combina-
tions may have heterogeneous effects on testing to establish
cure. The physicians who participated in this trial used
PPI-based triple or quadruple therapy. We would suggest
that these therapies are the ones that should be and are most
commonly used in clinical practice. As such, our protocol
simulated the behaviors of most clinicians treatingH. pylori
infection. Next, the eradication rate for all therapies used in
this protocol was 87%. As such, the high pretest probability
for a negative result likely contributed to the excellent NPV
for the 2-wk UBT. Regardless, the narrow 95% CI for the
specificity and NPV support the reliability of a negative test
result. Although the sensitivity of the 2-wk UBT was 90%,
our small sample size led to wide 95% CI (72–100%). A
larger study with a greater number of treatment failures will
be necessary to confirm or refute our result.
We have conducted the first study to evaluate the useful-
ness of the14C-urea breath test to confirmH. pylori eradi-
cation before the current standard of 4 wk after therapy. We
report encouraging results, particularly with regard to the
specificity and NPV of testing 2 wk after therapy. We hope
that our study will stimulate a reevaluation of the current
practice standard for testing to establishH. pylori eradica-
tion. Certainly, the ability to perform testing earlier than 1
month after therapy would afford patients and health care
professionals greater flexibility and allow more timely ac-
cess to clinically relevant information.
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